Harald Lahner

3.5k total citations
69 papers, 1.5k citations indexed

About

Harald Lahner is a scholar working on Epidemiology, Oncology and Neurology. According to data from OpenAlex, Harald Lahner has authored 69 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Epidemiology, 36 papers in Oncology and 26 papers in Neurology. Recurrent topics in Harald Lahner's work include Neuroendocrine Tumor Research Advances (41 papers), Lung Cancer Research Studies (30 papers) and Neuroblastoma Research and Treatments (25 papers). Harald Lahner is often cited by papers focused on Neuroendocrine Tumor Research Advances (41 papers), Lung Cancer Research Studies (30 papers) and Neuroblastoma Research and Treatments (25 papers). Harald Lahner collaborates with scholars based in Germany, United States and France. Harald Lahner's co-authors include Stephan Petersenn, Klaus Mann, Gerald Antoch, Thorsten D. Poeppel, Andreas Bockisch, Christian Boy, Ina Binse, M. Schott, Wolfgang Brandau and Iris Schmidt and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Harald Lahner

65 papers receiving 1.4k citations

Peers

Countries citing papers authored by Harald Lahner

Since Specialization

Citations

This map shows the geographic impact of Harald Lahner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harald Lahner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harald Lahner more than expected).

Fields of papers citing papers by Harald Lahner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harald Lahner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harald Lahner. The network helps show where Harald Lahner may publish in the future.

Co-authorship network of co-authors of Harald Lahner

This figure shows the co-authorship network connecting the top 25 collaborators of Harald Lahner. A scholar is included among the top collaborators of Harald Lahner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harald Lahner. Harald Lahner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center 2025 ·The Journal of Clinical Endocrinology & Metabolism ·(unknown), Tim Brandenburg, (unknown), Vera Tiedje, Sarah Theurer, Manuel Weber, Frank Weber, Henning Dralle, Harald Lahner, (unknown)	2
2	Stellenwert der Peptid-Radio-Rezeptor-Therapie für das Management neuroendokriner Tumoren 2025 ·Die Radiologie ·(unknown), Ken Herrmann, Harald Lahner	1
3	Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study 2024 ·The Oncologist ·Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, (unknown), (unknown), (unknown), (unknown), Markus Raderer	4
4	Hedinger Syndrome—Lessons Learnt: A Single-Center Experience 2023 ·Journal of Cardiovascular Development and Disease ·Mohamed El Gabry, (unknown), Sharaf-Eldin Shehada, Harald Lahner, Markus Kamler, Daniel Wendt, (unknown)	0
5	Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), (unknown), Robert Seifert, Benedikt M. Schaarschmidt, Wolfgang P. Fendler, Christoph Rischpler, Harald Lahner, Ken Herrmann, Anders Sundin	2
6	Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy 2022 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Kurt Werner Schmid, Henning Reis, Martin Stuschke, Jürgen Treckmann, P. M. Markus, Brigitte Schumacher, David Albers, (unknown), Harald Lahner, Marcel Wiesweg, Martin Schüler, Jens T. Siveke, Stefan Kasper	1
7	Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice 2022 ·Cancers ·(unknown), Christian Fottner, Harald Lahner, Henning Jann, (unknown), D. Quietzsch, Patricia Grabowski, Birgit Cremer, Sebastian Maasberg, Ulrich‐Frank Pape, Hans‐Helge Mueller, Thomas M. Gress, Anja Rinke, (unknown)	5
8	Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria 2021 ·Experimental and Clinical Endocrinology & Diabetes ·Anja Rinke, Christoph Maintz, Lothar Müller, Matthias M. Weber, Harald Lahner, Marianne Pavel, Wolfgang Saeger, Aude Houchard, (unknown), Stephan Petersenn	5
9	Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy 2021 ·Endocrine ·Harald Lahner, (unknown), (unknown), Nicole Unger, Jens Theysohn, Jan Rekowski, Karl‐Heinz Jöckel, Sarah Theurer, Kurt Werner Schmid, Ken Herrmann, Dagmar Führer	10
10	Phäochromozytomatose nach Adrenalektomie: Metastasierung oder Zellverschleppung? 2019 ·Der Chirurg ·Frank Weber, (unknown), Nicole Unger, Harald Lahner, Sarah Theurer, Kurt Werner Schmid, Dagmar Führer, Henning Dralle	2
11	Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT 2017 ·European Radiology ·Lino M. Sawicki, Cornelius Deuschl, Karsten Beiderwellen, Verena Ruhlmann, Thorsten D. Poeppel, Philipp Heusch, Harald Lahner, Dagmar Führer, Andreas Bockisch, Ken Herrmann, Michael Forsting, Gerald Antoch, Lale Umutlu	59
12	Impact of season and different vitamin D thresholds on prevalence of vitamin D deficiency in epidemiological cohorts—a note of caution 2017 ·Endocrine ·(unknown), Sara Schramm, Harald Lahner, Karl‐Heinz Jöckel, Raimund Erbel, Dagmar Führer, Susanne Moebus	39
13	Combined lanreotide autogel and temozolomide therapy in progressive neuroendocrine tumours: the SONNET study 2016 ·Annals of Oncology ·Dieter Hörsch, Markus Raderer, Harald Lahner, Anja Rinke, Timm Denecke, (unknown), (unknown), (unknown), Marianne Pavel	2
14	A Piece of the Puzzle: The Bone Health Index of the BoneXpert Software Reflects Cortical Bone Mineral Density in Pediatric and Adolescent Patients 2016 ·PLoS ONE ·Michael M. Schündeln, (unknown), (unknown), (unknown), Bernd Schweiger, Dagmar Führer‐Sakel, Harald Lahner, Thorsten D. Poeppel, (unknown), Berthold P. Hauffa, Corinna Grasemann	35
15	Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery 2010 ·European Journal of Endocrinology ·(unknown), Thomas R. Meinel, Harald Lahner, Klaus Mann, Stephan Petersenn	28
16	Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS) 2010 ·BMC Medical Genetics ·Susanne Tan, André Scherag, Onno E. Janßen, Susanne Hahn, Harald Lahner, Tiina Dietz, Susann Scherag, Harald Grallert, Carla Ivane Ganz Vogel, Rainer Kimmig, Thomas Illig, Klaus Mann, Johannes Hebebrand, Anke Hinney	83
17	Apoptotic Markers Indicate Nonalcoholic Steatohepatitis in Polycystic Ovary Syndrome 2009 ·The Journal of Clinical Endocrinology & Metabolism ·Susanne Tan, Lars P. Bechmann, Sven Benson, Tiina Dietz, (unknown), Susanne Hahn, Onno E. Janßen, Harald Lahner, Guido Gerken, Klaus Mann, Ali Canbay	44
18	Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance 2007 ·European Journal of Endocrinology ·Susanne Tan, Susanne Hahn, Sven Benson, Tiina Dietz, Harald Lahner, Lars C. Moeller, M Schmidt, Sigrid Elsenbruch, Rainer Kimmig, Klaus Mann, Onno E. Janßen	78
19	Rhabdomyolyse, Hyponatriämie und Fieber bei einem Patienten mit Schmidt-Syndrom 2003 ·DMW - Deutsche Medizinische Wochenschrift ·(unknown), (unknown), Harald Lahner, Thomas Schroeder, (unknown), Klaus Mann	2
20	Characterization and primary structures of bovine and porcine thyroxine-binding globulin 2002 ·Molecular and Cellular Endocrinology ·Onno E. Janßen, Harald Lahner, Helmut Grasberger, (unknown), Bernhard Saller, Klaus Mann, Samuel Refetoff, Ralf Einspanier	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact